newsfilter
← Latest News
GlobeNewswire·

SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics

Acquisition to Include Naxitamab-gqgk DANYELZA® (Naxitamab-gqgk), Further Broadening SERB's Rare Oncology Product Portfolio Transaction Expands SERB's Investment in the U.S. SERB to Commence All-Cash Tender Offer